David Bouhadana1, David-Dan Nguyen1, Brendan Raizenne2, Joe Schwarcz3, Harvey Gordon4, Bilal Chughtai5, Dean S Elterman4, Luke T Lavallée6, Paul Martin7, Kristen McAlpine4, Ryan Paterson8, Hassan Razvi9, Kevin C Zorn2, Naeem Bhojani2. 1. Faculty of Medicine, McGill University, Montreal, QC, Canada. 2. Division of Urology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada. 3. McGill University, Montreal, QC, Canada. 4. Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada. 5. Department of Urology, Weill Cornell Medical College/New York Presbyterian, New York, NY, United States. 6. Department of Surgery, Division of Urology, University of Ottawa, Ottawa, ON, Canada. 7. Bluewater Health, Sarnia, ON, Canada. 8. Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. 9. Division of Urology, Department of Surgery, Western University, London, ON, Canada.
Abstract
INTRODUCTION: The growing number of surgical options available to treat benign prostatic hyperplasia (BPH), may overwhelm patients and urologists when deciding on an optimal treatment. Therefore, we developed an online patient decision aid (PtDA) that includes all guideline-approved surgical modalities. The objective of this study was to assess the acceptability of the PtDA among former BPH surgery patients and urologists that treat BPH surgically. METHODS: The International Patient Decision Aids Standards were used to develop a PtDA that includes monopolar transurethral resection of the prostate (TURP), bipolar TURP, GreenLight photovaporization, endoscopic enucleation of the prostate, Rezum, Urolift, Aquablation, open retropubic prostatectomy, and robotic simple prostatectomy as management options. Eleven urologists that regularly treat BPH and 19 patients who received BPH surgery were recruited. Alpha-testing was performed using a validated acceptability scoring system. RESULTS: For all sections of the PtDA, most urologists agreed that the language used was easy to follow (91.9%), that the amount of information provided was adequate (63.6%), that the length of the PtDA was appropriate (63.6%), and that the outcomes reported were correct (81.8%). All 19 patient participants agreed that the language used was easy to follow, and most found that the amount of information provided was adequate (84.2%), that the length of the PtDA was appropriate (84.2%), and that the outcomes reported were well-explained (89.5%). CONCLUSIONS: Our PtDA was found to be acceptable among urologists and patients. These results demonstrate that most of the participants either recommend the use of this tool or plan to incorporate it in their clinical practice.
INTRODUCTION: The growing number of surgical options available to treat benign prostatic hyperplasia (BPH), may overwhelm patients and urologists when deciding on an optimal treatment. Therefore, we developed an online patient decision aid (PtDA) that includes all guideline-approved surgical modalities. The objective of this study was to assess the acceptability of the PtDA among former BPH surgery patients and urologists that treat BPH surgically. METHODS: The International Patient Decision Aids Standards were used to develop a PtDA that includes monopolar transurethral resection of the prostate (TURP), bipolar TURP, GreenLight photovaporization, endoscopic enucleation of the prostate, Rezum, Urolift, Aquablation, open retropubic prostatectomy, and robotic simple prostatectomy as management options. Eleven urologists that regularly treat BPH and 19 patients who received BPH surgery were recruited. Alpha-testing was performed using a validated acceptability scoring system. RESULTS: For all sections of the PtDA, most urologists agreed that the language used was easy to follow (91.9%), that the amount of information provided was adequate (63.6%), that the length of the PtDA was appropriate (63.6%), and that the outcomes reported were correct (81.8%). All 19 patient participants agreed that the language used was easy to follow, and most found that the amount of information provided was adequate (84.2%), that the length of the PtDA was appropriate (84.2%), and that the outcomes reported were well-explained (89.5%). CONCLUSIONS: Our PtDA was found to be acceptable among urologists and patients. These results demonstrate that most of the participants either recommend the use of this tool or plan to incorporate it in their clinical practice.
Authors: Dawn Stacey; France Légaré; Krystina Lewis; Michael J Barry; Carol L Bennett; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; Richard Thomson; Lyndal Trevena Journal: Cochrane Database Syst Rev Date: 2017-04-12
Authors: David Bouhadana; David-Dan Nguyen; Joe Schwarcz; Harvey Gordon; Dean S Elterman; Luke T Lavallée; Paul Martin; Kristen McAlpine; Ryan Paterson; Hassan Razvi; Kevin C Zorn; Naeem Bhojani Journal: BJU Int Date: 2021-01 Impact factor: 5.588
Authors: J Curtis Nickel; Lorne Aaron; Jack Barkin; Dean Elterman; Mahmoud Nachabé; Kevin C Zorn Journal: Can Urol Assoc J Date: 2018-10 Impact factor: 1.862
Authors: France Légaré; Stephen Kearing; Kate Clay; Susie Gagnon; Denis D'Amours; Michel Rousseau; Annette O'Connor Journal: Can Fam Physician Date: 2010-08 Impact factor: 3.275
Authors: Kristen McAlpine; Luke T Lavallée; Dawn Stacey; Preveshen Moodley; Ilias Cagiannos; Christopher Morash; Peter C Black; Girish S Kulkarni; Bobby Shayegan; Wassim Kassouf; Robert Siemens; Alan So; Michael J Leveridge; Stephen A Boorjian; Siamak Daneshmand; Angela B Smith; Nicholas Power; Jonathan Izawa; Darrel E Drachenberg; Adrian Fairey; Ricardo A Rendon; Rodney H Breau Journal: J Urol Date: 2019-10-09 Impact factor: 7.450
Authors: Harris E Foster; Philipp Dahm; Tobias S Kohler; Lori B Lerner; J Kellogg Parsons; Timothy J Wilt; Kevin T McVary Journal: J Urol Date: 2019-08-08 Impact factor: 7.450